Genprex, Inc. announced that it has expanded its oncology research and development pipeline to include small cell lung cancer (SCLC) as an additional disease indication for its lead drug candidate, REQORSA™ Immunogene Therapy. SCLC represents approximately 10%-15% of the lung cancer market, while REQORSA's initial target indication of non-small cell lung cancer (NSCLC) represents approximately 84% of the lung cancer market. REQORSA consists of a TUSC2 gene expressing plasmid encapsulated in non-viral lipid nanoparticles.

Genprex's oncology program utilizes its unique, proprietary, non-viral ONCOPREX® Nanoparticle Delivery System, which the Company believes is the first systemic gene therapy delivery platform used for cancer in humans. The ONCOPREX Nanoparticle Delivery System could allow for the delivery of a number of cancer-fighting genes, alone or in combination with other cancer therapies to potentially address unmet medical need in cancer, thereby potentially improving patient outcomes through the advancement of multiple therapeutic approaches for large patient populations.